- Home
- SXTP vs VIVS Comparison
SXTP vs VIVS Comparison
Compare SXTP & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SXTP | VIVS |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.5M |
| IPO Year | 2023 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SXTP | VIVS |
|---|---|---|
| Price | $1.06 | $0.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.10 | N/A |
| AVG Volume (30 Days) | 78.3K | ★ 5.8M |
| Earning Date | 05-15-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,005,471.00 | ★ $4,603,000.00 |
| Revenue This Year | $33.92 | $42.38 |
| Revenue Next Year | $51.35 | $15.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.49 | 8.82 |
| 52 Week Low | $0.34 | $0.26 |
| 52 Week High | $8.62 | $5.30 |
Technical Indicators
Market Signals| Indicator | SXTP | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 35.82 | 30.48 |
| Support Level | $1.05 | $0.26 |
| Resistance Level | $1.12 | $0.58 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 24.00 | 18.48 |
Price Performance
Historical ComparisonAbout SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.